Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study

Authors

• Toby A. Eyre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom
• Nicolás Martínez-Calle, Nottingham Children’s Hospital, Nottingham University Hospitals NHS Trust, Queen’s Medical Centre, Nottingham, United Kingdom.
• Shankara Paneesha, University Hospitals Birmingham NHS Foundation Trust
• Mohsen Norouzi, James Cook University Hospital, Middlesbrough, United Kingdom
• David L Tucker, Royal Cornwall Hospital Trust, Truro, United Kingdom
• Harriet Sarah Walter, School of Healthcare, College of Life Sciences, University of Leicester, Leicester, United Kingdom.
• Alison Boden, United Lincolnshire Hospitals NHS Trust,, Lincoln, United Kingdom
• Mari Kilner, North Tyneside General Hospital, North Shields, United Kingdom
• Neil Phillips, University Hospitals of North Midlands Trust, Stoke on Trent, United Kingdom
• Piers EM Patten, King's College Hospital, United Kingdom
• Nimish Shah, Norfolk and Norwich University Hospital, Norwich, United Kingdom
• Meghna Ruparelia, Royal Derby Hospital, Derby, United Kingdom
• Sharon Oddy, Mid Yorkshire Teaching Hospital NHS Trust, Wakefield, United Kingdom
• Tan Tsawayo, East Sussex Healthcare NHs Trust, St Leonards-on-Sea, United Kingdom
• Francesco Forconi, University of Southampton, Southampton, United Kingdom
• Helen Wardle, University Hospital of North Tees, Stockton-on-Tees, United Kingdom
• Tobore Gbemre, Doncaster and Bassetlaw Teaching Hospitals NHS Trust, Doncaster, United Kingdom
• Chris Gregory, Royal Albert Edward Infirmary, Wigan, United Kingdom
• Lucy B. M. Cook, Imperial College NHS Healthcare Trust, London, United Kingdom
• David J Allsup, University of Hull, Hull, United Kingdom
• Anna Morris, Dorset County Hospital NHS Trust, Dorchester, United Kingdom
• Christopher J C Knechtli, Royal United Hospital NHS Foundation Trust Bath, Bath, United Kingdom
• Jenni Davies, University Hospital of Wales, Cardiff, Cardiff, United Kingdom
• Joy Galani, Dartford and Gravesham NHS Trust, Darent Valley Hospital, Dartford, United Kingdom
• Helen Marr, Newcastle Teaching Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
• Claire Hutchinson, Peninsula Medical School
• Stella Williams, Clatterbridge Cancer Centre, Liverpool, United Kingdom
• Joe Hickey, OPEN Health, London, United Kingdom
• Hannah Harding, AstraZeneca, London, United Kingdom
• Sukhjit Hunjan, AstraZeneca, London, United Kingdom

ORCID

• Claire Hutchinson: 0000-0003-2314-6558

DOI Link

10.1182/bloodadvances.2026019978

Publication Date

2026-04-29

Publication Title

Blood advances

ISSN

2473-9529

Acceptance Date

2026-04-07

Deposit Date

2026-07-14

Additional Links

https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2026019978/568092/Acalabrutinib-monotherapy-as-a-first-line

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.

Recommended Citation

Eyre, T., Martínez-Calle, N., Paneesha, S., Norouzi, M., Tucker, D., Walter, H., Boden, A., Kilner, M., Phillips, N., Patten, P., Shah, N., Ruparelia, M., Oddy, S., Tsawayo, T., Forconi, F., Wardle, H., Gbemre, T., Gregory, C., Cook, L., Allsup, D., Morris, A., Knechtli, C., Davies, J., Galani, J., Marr, H., Hutchinson, C., Williams, S., Hickey, J., Harding, H., & Hunjan, S. (2026) 'Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study', Blood advances, . Available at: 10.1182/bloodadvances.2026019978